Donatello Laera

Dr. Donatello Laera

TRD-Drug Product, GlaxoSmithKline (Italy), Verona, Veneto, Italy
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
TWTom Y.-H. Wu
Tom Y.-H. Wu
MSManmohan Singh
Manmohan Singh
AMAndrew T. Miller
Andrew T. Miller
EGEnnio De Gregorio
Ennio De Gregorio
FDFrancesco Doro
Francesco Doro
NVNicholas M. Valiante
Nicholas M. Valiante
Small-molecule immune potentiators can be engineered to be potent adjuvants with localized innate immune activation and short in vivo residence times.

1 January 2013 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
PDF file
EBErika Bartolini
Erika Bartolini
EIElvira Ianni
Elvira Ianni
EFElisabetta Frigimelica
Elisabetta Frigimelica
RPRoberto Petracca
Roberto Petracca
GGGiuliano Galli
Giuliano Galli
RGRenata Grifantini
Renata Grifantini
Background: Outer membrane vesicles (OMVs) are spheroid particles released by all Gram‐negative bacteria as a result of the budding out of the outer membrane. Since they carry many of the bacterial surface‐associated proteins and feature a potent built‐in adjuvanticity, OMVs are being utilized as vaccines, some of which commercially available. Recently, methods for manipulating the protein content of OMVs have been proposed, thus making OMVs a promising platform for recombinant, multivalent vaccines development.Methods: Chlamydia muridarum DO serine protease HtrA, an antigen which stimulates strong humoral and cellular responses in mice and humans, was expressed in Escherichia coli fused to the OmpA leader sequence to deliver it to the OMV compartment. Purified OMVs carrying HtrA (CM rHtrA‐OMV) were analyzed for their capacity to induce antibodies capable of neutralizing Chlamydia infection of LLC‐MK2 cells in vitro.Results: CM rHtrA‐OMV immunization in mice induced antibodies that neutralize Chlamydial invasion as judged by an in vitro infectivity assay. This was remarkably different from what observed with an enzymatically functional recombinant HtrA expressed in, and purified from the E. coli cytoplasm (CM rHtrA). The difference in functionality between anti‐CM rHtrA and anti‐CM rHtrA‐OMV antibodies was associated to a different pattern of protein epitopes recognition. The epitope recognition profile of anti‐CM HtrA‐OMV antibodies was similar to that induced in mice during Chlamydial infection.Conclusions: When expressed in OMVs HtrA appears to assume a conformation similar to the native one and this results in the elicitation of functional immune responses. These data further support the potentiality of OMVs as vaccine platform.

4 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DLDonatello Laera
Donatello Laera
Harm HogenEschHarm HogenEsch
Harm HogenEsch
Derek O'haganDerek O'hagan
Derek O'hagan
Aluminum-based adjuvants will continue to be a key component of currently approved and next generation vaccines, including important combination vaccines. The widespread use of aluminum adjuvants is due to their excellent safety profile, which has been established through the use of hundreds of millions of doses in humans over many years. In addition, they are inexpensive, readily available, and are well known and generally accepted by regulatory agencies. Moreover, they offer a very flexible platform, to which many vaccine components can be adsorbed, enabling the preparation of liquid formulations, which typically have a long shelf life under refrigerated conditions. Nevertheless, despite their extensive use, they are perceived as relatively ‘weak’ vaccine adjuvants. Hence, there have been many attempts to improve their performance, which typically involves co-delivery of immune potentiators, including Toll-like receptor (TLR) agonists. This approach has allowed for the development of improved aluminum adjuvants for inclusion in licensed vaccines against HPV, HBV, and COVID-19, with others likely to follow. This review summarizes the various aluminum salts that are used in vaccines and highlights how they are prepared. We focus on the analytical challenges that remain to allowing the creation of well-characterized formulations, particularly those involving multiple antigens. In addition, we highlight how aluminum is being used to create the next generation of improved adjuvants through the adsorption and delivery of various TLR agonists.

31 May 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
OFOretta Finco
Oretta Finco
EFElisabetta Frigimelica
Elisabetta Frigimelica
FBFrancesca Buricchi
Francesca Buricchi
RPRoberto Petracca
Roberto Petracca
GGGiuliano Galli
Giuliano Galli
RGRenata Grifantini
Renata Grifantini
Natural immunity against obligate and/or facultative intracellular pathogens is usually mediated by both humoral and cellular immunity. The identification of those antigens stimulating both arms of the immune system is instrumental for vaccine discovery. Although high-throughput technologies have been applied for the discovery of antibody-inducing antigens, few examples of their application for T-cell antigens have been reported. We describe how the compilation of the immunome, here defined as the pool of immunogenic antigens inducing T- and B-cell responses in vivo, can lead to vaccine candidates against Chlamydia trachomatis . We selected 120 C. trachomatis proteins and assessed their immunogenicity using two parallel high-throughput approaches. Protein arrays were generated and screened with sera from C. trachomatis -infected patients to identify antibody-inducing antigens. Splenocytes from C. trachomatis -infected mice were stimulated with 79 proteins, and the frequency of antigen-specific CD4 + /IFN-γ + T cells was analyzed by flow cytometry. We identified 21 antibody-inducing antigens, 16 CD4 + /IFN-γ + –inducing antigens, and five antigens eliciting both types of responses. Assessment of their protective activity in a mouse model of Chlamydia muridarum lung infection led to the identification of seven antigens conferring partial protection when administered with LTK63/CpG adjuvant. Protection was largely the result of cellular immunity as assessed by CD4 + T-cell depletion. The seven antigens provided robust additive protection when combined in four-antigen combinations. This study paves the way for the development of an effective anti- Chlamydia vaccine and provides a general approach for the discovery of vaccines against other intracellular pathogens.

15 August 2015 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
GLGiuseppe Lofano
Giuseppe Lofano
FMFrancesca Mancini
Francesca Mancini
GSGiulia Salvatore
Giulia Salvatore
RCRocco Cantisani
Rocco Cantisani
EMElisabetta Monaci
Elisabetta Monaci
SBSylvie Bertholet
Sylvie Bertholet
Induction of persistent protective immune responses is a key attribute of a successful vaccine formulation. MF59 adjuvant, an oil-in-water emulsion used in human vaccines, is known to induce persistent high-affinity functional Ab titers and memory B cells, but how it really shapes the Ag-specific B cell compartment is poorly documented. In this study, we characterized the Ab- and Ag-specific B cell compartment in wild-type mice immunized with HlaH35L, a Staphylococcus aureus Ag known to induce measurable functional Ab responses, formulated with MF59 or aluminum salts, focusing on germinal centers (GC) in secondary lymphoid organs. Taking advantage of single-cell flow cytometry analyses, HlaH35L-specific B cells were characterized for the expression of CD38 and GL-7, markers of memory and GC, respectively, and for CD80 and CD73 activation markers. We demonstrated that immunization with MF59-, but not aluminum salt–adjuvanted HlaH35L, induced expanded Ag-specific CD73+CD80− GC B cells in proximal- and distal-draining lymph nodes, and promoted the persistence of GC B cells, detected up to 4 mo after immunization. In addition to increasing GC B cells, MF59-adjuvanted HlaH35L also increased the frequency of T follicular helper cells. This work extends previous knowledge regarding adaptive immune responses to MF59-adjuvanted vaccines, and, to our knowledge, for the first time an adjuvant used in human licensed products is shown to promote strong and persistent Ag-specific GC responses that might benefit the rational design of new vaccination strategies.

26 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FMFrancesca Mancini
Francesca Mancini
EMElisabetta Monaci
Elisabetta Monaci
GLGiuseppe Lofano
Giuseppe Lofano
ATAntonina Torre
Antonina Torre
MBMarta Bacconi
Marta Bacconi
SBSylvie Bertholet
Sylvie Bertholet
A rapidly acting, single dose vaccine against Staphylococcus aureus would be highly beneficial for patients scheduled for major surgeries or in intensive care units. Here we show that one immunization with a multicomponent S. aureus candidate vaccine, 4C-Staph, formulated with a novel TLR7-dependent adjuvant, T7-alum, readily protected mice from death and from bacterial dissemination, both in kidney abscess and peritonitis models, outperforming alum-formulated vaccine. This increased efficacy was paralleled by higher vaccine-specific and α-hemolysin-neutralizing antibody titers and Th1/Th17 cell responses. Antibodies played a crucial protective role, as shown by the lack of protection of 4C-Staph/T7-alum vaccine in B-cell-deficient mice and by serum transfer experiments. Depletion of effector CD4+ T cells not only reduced survival but also increased S. aureus load in kidneys of mice immunized with 4C-Staph/T7-alum. The role of IL-17A in the control of bacterial dissemination in 4C-Staph/T7-alum vaccinated mice was indicated by in vivo neutralization experiments. We conclude that single dose 4C-Staph/T7-alum vaccine promptly and efficiently protected mice against S. aureus through the combined actions of antibodies, CD4+ effector T cells, and IL-17A. These data suggest that inclusion of an adjuvant that induces not only fast antibody responses but also IL-17-producing cell-mediated effector responses could efficaciously protect patients scheduled for major surgeries or in intensive care units.